For its fourth fiscal quarter (ending December 31), Amedisys Inc (NASDAQ: AMED) has reported a -205% decline in E.P.S. from $0.59 a year ago to $-0.62 in the current quarter. E.P.S. were $1.32 for the latest four quarters through December 31 versus $-0.30 for the same period a year ago — a decline of -540%.
Recent Price Action
On 2/26/25, Amedisys Inc (NASDAQ: AMED) stock rose slightly by 0.03%, closing at $91.57. Moreover, above average trading volume at 121% of normal accompanied the advance. Relative to the market the stock has been weak over the last nine months and has declined -1.1% during the last week.
Current PriceTarget Research Rating
Amedisys has a current Value Trend Rating of D (Negative). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Amedisys has a neutral Power Rating of 46 and a slightly negative Appreciation Score of 34, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment